Cargando…
The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
BACKGROUND: Data suggest that vancomycin + β-lactam combinations improve clearance of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates the impact of concomitant empiric cefepime o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446134/ https://www.ncbi.nlm.nih.gov/pubmed/30968053 http://dx.doi.org/10.1093/ofid/ofz079 |
_version_ | 1783408306017009664 |
---|---|
author | Zasowski, Evan J Trinh, Trang D Atwan, Safana M Merzlyakova, Marina Langf, Abdalhamid M Bhatia, Sahil Rybak, Michael J |
author_facet | Zasowski, Evan J Trinh, Trang D Atwan, Safana M Merzlyakova, Marina Langf, Abdalhamid M Bhatia, Sahil Rybak, Michael J |
author_sort | Zasowski, Evan J |
collection | PubMed |
description | BACKGROUND: Data suggest that vancomycin + β-lactam combinations improve clearance of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates the impact of concomitant empiric cefepime on outcomes of MRSA BSIs treated with vancomycin. METHODS: Retrospective cohort study of adults with MRSA BSI from 2006 to 2017. Vancomycin + cefepime therapy was defined as ≥24 hours of cefepime during the first 72 hours of vancomycin. The primary outcome was microbiologic failure, defined as BSI duration ≥7 days and/or 60-day recurrence. Multivariable logistic regression was used to evaluate the association between vancomycin + cefepime therapy and binary outcomes. Cause-specific and subdistribution hazard models were used to evaluate the association between vancomycin + cefepime and BSI clearance. RESULTS: Three hundred fifty-eight patients were included, 129 vancomycin and 229 vancomycin + cefepime. Vancomycin + cefepime therapy was independently associated with reduced microbiologic failure (adjusted odds ratio [aOR], 0.488; 95% confidence interval [CI], 0.271–0.741). This was driven by a reduction in the incidence of BSI durations ≥7 days (vancomycin + cefepime aOR, 0.354; 95% CI, 0.202–0.621). Vancomycin + cefepime had no association with 30-day mortality (aOR, 0.952; 95% CI, 0.435–2.425). Vancomycin + cefepime was associated with faster BSI clearance in both cause-specific (HR, 1.408; 95% CI, 1.125–1.762) and subdistribution hazard models (HR, 1.264; 95% CI, 1.040–1.536). CONCLUSIONS: Concomitant empiric cefepime improved MRSA BSI clearance and may be useful as the β-lactam component of synergistic vancomycin + β-lactam regimens when empiric or directed gram-negative coverage is desired. |
format | Online Article Text |
id | pubmed-6446134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64461342019-04-09 The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin Zasowski, Evan J Trinh, Trang D Atwan, Safana M Merzlyakova, Marina Langf, Abdalhamid M Bhatia, Sahil Rybak, Michael J Open Forum Infect Dis Major Articles BACKGROUND: Data suggest that vancomycin + β-lactam combinations improve clearance of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates the impact of concomitant empiric cefepime on outcomes of MRSA BSIs treated with vancomycin. METHODS: Retrospective cohort study of adults with MRSA BSI from 2006 to 2017. Vancomycin + cefepime therapy was defined as ≥24 hours of cefepime during the first 72 hours of vancomycin. The primary outcome was microbiologic failure, defined as BSI duration ≥7 days and/or 60-day recurrence. Multivariable logistic regression was used to evaluate the association between vancomycin + cefepime therapy and binary outcomes. Cause-specific and subdistribution hazard models were used to evaluate the association between vancomycin + cefepime and BSI clearance. RESULTS: Three hundred fifty-eight patients were included, 129 vancomycin and 229 vancomycin + cefepime. Vancomycin + cefepime therapy was independently associated with reduced microbiologic failure (adjusted odds ratio [aOR], 0.488; 95% confidence interval [CI], 0.271–0.741). This was driven by a reduction in the incidence of BSI durations ≥7 days (vancomycin + cefepime aOR, 0.354; 95% CI, 0.202–0.621). Vancomycin + cefepime had no association with 30-day mortality (aOR, 0.952; 95% CI, 0.435–2.425). Vancomycin + cefepime was associated with faster BSI clearance in both cause-specific (HR, 1.408; 95% CI, 1.125–1.762) and subdistribution hazard models (HR, 1.264; 95% CI, 1.040–1.536). CONCLUSIONS: Concomitant empiric cefepime improved MRSA BSI clearance and may be useful as the β-lactam component of synergistic vancomycin + β-lactam regimens when empiric or directed gram-negative coverage is desired. Oxford University Press 2019-04-03 /pmc/articles/PMC6446134/ /pubmed/30968053 http://dx.doi.org/10.1093/ofid/ofz079 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Major Articles Zasowski, Evan J Trinh, Trang D Atwan, Safana M Merzlyakova, Marina Langf, Abdalhamid M Bhatia, Sahil Rybak, Michael J The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title | The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title_full | The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title_fullStr | The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title_full_unstemmed | The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title_short | The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin |
title_sort | impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant staphylococcus aureus bloodstream infections treated with vancomycin |
topic | Major Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446134/ https://www.ncbi.nlm.nih.gov/pubmed/30968053 http://dx.doi.org/10.1093/ofid/ofz079 |
work_keys_str_mv | AT zasowskievanj theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT trinhtrangd theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT atwansafanam theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT merzlyakovamarina theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT langfabdalhamidm theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT bhatiasahil theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT rybakmichaelj theimpactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT zasowskievanj impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT trinhtrangd impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT atwansafanam impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT merzlyakovamarina impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT langfabdalhamidm impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT bhatiasahil impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin AT rybakmichaelj impactofconcomitantempiriccefepimeonpatientoutcomesofmethicillinresistantstaphylococcusaureusbloodstreaminfectionstreatedwithvancomycin |